COMPANY NEWS
1 min read
MST Access research report
MST Access has published a research report on Lumos Diagnostics Limited.
Read article
News
Featured news
COMPANY NEWS
COMPANY NEWS
2 min read
FebriDx® Commercial Traction Continues to Advance
Lumos Diagnostics has announced further progress in the U.S. commercialisation of FebriDx® across its priority top-100 urgent care target list.
Read article
COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
Read articleAll news
COMPANY NEWS
1 min read
Texas A&M University Health Services Adopts FebriDx® in Student Medical Centers
Lumos Diagnostics (ASX: LDX) is pleased to share that Texas A&M University Health Services has commenced the routine use of FebriDx®
Read article
COMPANY NEWS
1 min read
Lumos commences FebriDx® CLIA waived pediatric study
Lumos has commenced its FebriDx® CLIA-waiver pediatric study in the United States, with the first patient successfully enrolled.
Read article
COMPANY NEWS
1 min read
Proactive Interview with CFO Barrie Lambert
In this interview, Lumos’ CFO Barrie Lambert discusses Lumos’ upcoming paediatric study designed to expand FebriDx®...
Read article
COMPANY NEWS
1 min read
Lumos Diagnostics Signs Second ANZ Distribution Agreement for FebriDx®
Lumos Diagnostics has signed a new distribution agreement with Amtech, part of the YesGroup alliance
Read article
COMPANY NEWS
1 min read
Lumos FY25 Results Investor Briefing
During this briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell provide an overview of the FY25 results and a general business update.
Read article
COMPANY NEWS
1 min read
Lumos secures follow-on contract with Aptatek Biosciences for development of PKU in-home monitoring device
Lumos has secured a follow-on contract with Aptatek Biosciences to advance the PheCheck™ in-home monitoring device for phenylketonuria (PKU).
Read article
COMPANY NEWS
1 min read
Lumos and BARDA partner to undertake an additional clinical study to evaluate use of FebriDx®in U.S. CLIA-waived pediatric settings
Lumos Diagnostics has announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded US$6.2 million in non-dilutive funding to support a new U.S. paediatric study of our flagship FebriDx® test.
Read article
COMPANY NEWS
2 min read
Submission of CLIA Waiver Application for FebriDx®
Lumos Diagnostics has announced the completion of the clinical study and submission of its application to the U.S...
Read article
COMPANY NEWS
2 min read
Lumos Diagnostics Partners with PRO-spectus to Accelerate Market Access for FebriDx
Lumos Diagnostics has today announced that it has entered into a partnering agreement with US-based market access consultancy...
Read article
COMPANY NEWS
1 min read
Lumos Signs Binding Term Sheet for A$5.0 million Loan Facility
Lumos has announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital.
Read article
COMPANY NEWS
2 min read
Lumos Diagnostics Signs Exclusive U.S. Distribution and Supply Agreement with PHASE Scientific for FebriDx®
Lumos has today announced a pivotal commercial development for its breakthrough diagnostic product, FebriDx®
Read article
COMPANY NEWS
1 min read
Video | Investor Briefing | PHASE Scientific Agreement
Lumos held an investor briefing outlining the transformational US$317 million distribution agreement with PHASE Scientific.
Read article